| have demonstrated that the lymphoid leukemia-associated protein, PAX5-PML chimeric oncogenic protein, could bind to PAX5 response-element as homodimer to inhibit the transactivation of PAX5 target-genes | leukemia, |
| Our findings unveil a novel essential oncogenic activity of PML/RARA in Acute promyelocitic leukemia | leukemia, |
| The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. | leukemia, |
| An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. | leukemia, |
| Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. | None |
| Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs). | None |
| PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. | None |
| PML is induced by oncogenic ras and promotes premature senescence. | None |
| PML and the oncogenic nuclear domains in regulating transcriptional repression. | None |
| Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF. | None |
| Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression. | None |
| Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. | None |
| Identification of PML oncogenic domains (PODs) in human megakaryocytes. | None |
| Recruitment of NBS1 into PML oncogenic domains via interaction with SP100 protein. | None |
| Distinct nuclear body components, PML and SMRT, regulate the trans-acting function of HTLV-1 Tax oncoprotein. | None |
| ZIP kinase triggers apoptosis from nuclear PML oncogenic domains. | None |
| The fusion oncoprotein PML-RARalpha induces endoplasmic reticulum (ER)-associated degradation of N-CoR and ER stress. | None |
| interference by human Cytomegalovirus IE1 protein with both the sumoylation of PML and its repressor activity requires a physical interaction with PML that also leads to disruption of PML oncogenic domains (PODs). | None |
| inhibition of monocyte differentiation all contribute to the oncogenic activity of PML-RARalpha | None |
| RXR is an essential component of the oncogenic PML/RARA complex in vivo. | None |